These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632 [TBL] [Abstract][Full Text] [Related]
4. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. Jorgensen SCJ; Tse CLY; Burry L; Dresser LD Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785 [TBL] [Abstract][Full Text] [Related]
5. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice. Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132 [TBL] [Abstract][Full Text] [Related]
6. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739 [TBL] [Abstract][Full Text] [Related]
7. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836 [TBL] [Abstract][Full Text] [Related]
8. Immunopathogenesis and treatment of cytokine storm in COVID-19. Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477 [TBL] [Abstract][Full Text] [Related]
9. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. Solimani F; Meier K; Ghoreschi K Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065 [TBL] [Abstract][Full Text] [Related]
10. JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids. Nystrom SE; Li G; Datta S; Soldano KL; Silas D; Weins A; Hall G; Thomas DB; Olabisi OA JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35472001 [TBL] [Abstract][Full Text] [Related]
11. Baricitinib set to join the Covid-19 therapeutic arsenal? Gudu T; Stober C; Cope AP; Cheriyan J; Galloway J; Wilkinson IB; Kostapanos M; Jayne D; Hall F Rheumatology (Oxford); 2021 Apr; 60(4):1585-1587. PubMed ID: 33502499 [No Abstract] [Full Text] [Related]
12. Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release. Chan M; Vijay S; McNevin J; McElrath MJ; Holland EC; Gujral TS Mol Syst Biol; 2021 Sep; 17(9):e10426. PubMed ID: 34486798 [TBL] [Abstract][Full Text] [Related]
16. The effect of drugs used in rheumatology for treating SARS-CoV2 infection. Atzeni F; Gerratana E; Giallanza M; La Corte L; Nucera V; Miceli G; Sangari D; Masala IF Expert Opin Biol Ther; 2021 Feb; 21(2):219-228. PubMed ID: 32866053 [TBL] [Abstract][Full Text] [Related]
17. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. Akbarzadeh-Khiavi M; Torabi M; Rahbarnia L; Safary A Infection; 2022 Apr; 50(2):295-308. PubMed ID: 34902115 [TBL] [Abstract][Full Text] [Related]
18. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562 [TBL] [Abstract][Full Text] [Related]
19. Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary. Gáspár Z; Szabó BG; Andrikovics H; Ceglédi A; Rajmon M; Ábrahám A; Várnai Z; Kiss-Dala N; Szlávik J; Sinkó J; Vályi-Nagy I; Lakatos B Geroscience; 2024 Jun; 46(3):2863-2877. PubMed ID: 38367195 [TBL] [Abstract][Full Text] [Related]
20. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache? Harigai M; Honda S Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]